Patent · US Active

Use of GABAA receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness

US9616070B2 · kind B2 · utility

0Cited by
4References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 12, 2009
Grant dateApr 11, 2017
Priority date—
Expiry dateMar 10, 2030

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P25/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersonmia; endozepine related recurrent stupor; and amphetamine resistant hypersonmia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.